Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Managing obesity with pharmacotherapy
Diabetes, Metabolic Syndrome and Obesity
ISSN: 1178-7007
- View all (2712)
- Volume 17, 2024 (267)
- Volume 16, 2023 (373)
- Volume 15, 2022 (350)
- Volume 14, 2021 (449)
- Volume 13, 2020 (486)
- Volume 12, 2019 (269)
- Volume 11, 2018 (92)
- Volume 10, 2017 (52)
- Volume 9, 2016 (45)
- Volume 8, 2015 (59)
- Volume 7, 2014 (61)
- Volume 6, 2013 (50)
- Volume 5, 2012 (41)
- Volume 4, 2011 (46)
- Volume 3, 2010 (45)
- Volume 2, 2009 (22)
- Volume 1, 2008 (5)
Journal Articles:
- Managing obesity with pharmacotherapy (6)
- Understanding the Impact of Gender and Sex on Diabetes Incidence, Complications, and Treatment (1)
- Emerging therapeutic targets of diabetic nephropathy (1)
Managing obesity with pharmacotherapy
Obesity is a chronic, relapsing, progressive disease causing or negatively impacting numerous medical conditions, including diabetes mellitus, cardiovascular disease, and some types of cancer. The foundation of its treatment is lifestyle modification. However, for many people with obesity, these changes are difficult to achieve and to maintain long-term. For this reason, great efforts have been made to develop effective drugs weight-reducing drugs. In the past, pharmacotherapy for obesity produced discouragingly modest weight loss on the whole, and several drugs had to be withdrawn from the market due to unacceptably severe side effects. However, the future of obesity pharmacotherapy looks promising. This Article Collection gathers studies in the area of pharmacological treatment of obesity, including preclinical studies, clinical trials, and reviews.
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity
Dalle Grave R
Diabetes, Metabolic Syndrome and Obesity 2024, 17:227-230
Published Date: 15 January 2024
The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Lv X, Wang H, Chen C, Zhao Y, Li K, Wang Y, Wang L, Fu S, Liu J
Diabetes, Metabolic Syndrome and Obesity 2024, 17:701-714
Published Date: 12 February 2024
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus
Shao Y, Chen Y, Zhu M, Liu Y, Fang C, Wang M, Sun P, Fu W, Huang J, Sheng S, Huang Y
Diabetes, Metabolic Syndrome and Obesity 2024, 17:1563-1573
Published Date: 6 April 2024
Effect of SophorOx® on Oxidative Stress and Body Composition in Individuals with High BMI: A Randomized Controlled Trial
Roza JM, Srivastava S
Diabetes, Metabolic Syndrome and Obesity 2024, 17:2221-2234
Published Date: 5 June 2024
The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets
Reed J, Bain SC, Kanamarlapudi V
Diabetes, Metabolic Syndrome and Obesity 2024, 17:2419-2456
Published Date: 13 June 2024
Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Patients with Overweight/Obesity
She D, Xu W, Liu J, Zhang Z, Fang P, Li R, Kong D, Xuan M, Liu Q, Pan MY, Wang Y, Xue Y
Diabetes, Metabolic Syndrome and Obesity 2023, 16:3007-3017
Published Date: 28 September 2023